Cue Biopharma
CUE
37 hedge funds and large institutions have $32.4M invested in Cue Biopharma in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 16 increasing their positions, 7 reducing their positions, and 5 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 7
125% more capital inflows, than outflows
Capital inflows: $6.53M | Capital outflows: $2.91M
2.14% more ownership
Funds ownership: 15.64% → 17.78% (+2.1%)
5% less funds holding
Funds holding: 39 → 37 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.14M |
| 2 |
State Street
Boston,
Massachusetts
|
+$496K |
| 3 |
P.A.W. Capital
Greenwich,
Connecticut
|
+$482K |
| 4 |
Morgan Stanley
New York
|
+$378K |
| 5 |
BlackRock
New York
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$2.31M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$179K |
| 3 |
Silverleafe Capital Partners
Germantown,
Tennessee
|
-$166K |
| 4 |
Goldman Sachs
New York
|
-$147K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$64.7K |
CUE Hedge Fund Activity: Q3 2018 in Review
37 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2018, worth a combined $32.4M — down 13% from $37.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CUE and 3 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 16 added.
The largest buyer was Nantahala Capital Management, adding an estimated $4.14M. The largest seller was First Eagle Investment Management, exiting entirely with an estimated $2.31M sold.
- 37 institutional investors held Cue Biopharma (CUE) as of Q3 2018, down from 39 in Q2 2018.
- Funds reported $32.4M of Cue Biopharma stock for Q3 2018, down 13% quarter-over-quarter.
- 3 funds opened new Cue Biopharma positions in Q3 2018 and 5 closed out, a net change of -2 holders.
- The largest Cue Biopharma buyer in Q3 2018 was Nantahala Capital Management, an estimated $4.14M added.
- The largest Cue Biopharma seller in Q3 2018 was First Eagle Investment Management, an estimated $2.31M sold.
Based on aggregated 13F filings for Q3 2018.